Page last updated: 2024-11-07

parinaric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Parinaric acid is a conjugated tetraenoic fatty acid found in the seeds of the genus *Impatiens*. It is a colorless oil that is insoluble in water but soluble in organic solvents. It is a powerful antioxidant and has been shown to have anti-inflammatory and anticancer effects. Parinaric acid is also a potent inhibitor of the enzyme cyclooxygenase (COX), which is involved in the production of prostaglandins, which are inflammatory mediators. This makes parinaric acid a potential therapeutic agent for the treatment of inflammatory diseases, such as arthritis and asthma. Parinaric acid is also being studied for its potential to prevent cardiovascular disease and cancer. It is a potent inhibitor of the enzyme lipoxygenase (LOX), which is involved in the production of leukotrienes, which are inflammatory mediators that contribute to the development of cardiovascular disease. Parinaric acid has also been shown to inhibit the growth of cancer cells in vitro and in vivo. The synthesis of parinaric acid is a complex process that involves the conversion of linoleic acid to parinaric acid. This process is catalyzed by the enzyme linoleate desaturase. Parinaric acid is also produced by some microorganisms, such as bacteria and fungi. Because of its unique structure and biological activities, parinaric acid has become a subject of intense research interest. It is being studied for its potential therapeutic applications in a wide range of diseases, including cancer, inflammatory diseases, cardiovascular disease, and neurodegenerative diseases. '

parinaric acid: long-chain polyenoic fatty acid; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

parinaric acid : An octadecatetraenoic acid containing a conjugated system of double bonds at positions 9, 11, 13 and 15. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID107981
CHEBI ID32408
SCHEMBL ID42083
MeSH IDM0061575

Synonyms (11)

Synonym
9,11,13,15-octadecatetraenoic acid
CHEBI:32408
c18:4 (n-3)
18:4 (n-3)
octadeca-9,11,13,15-tetraenoic acid
parinaric acid
9z,11e,13e,15z-octadecatetraenoic acid
SCHEMBL42083
DTXSID80172193
Q27114920
DTXSID501317170

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Parinaric acid, a naturally occurring 18-carbon fatty acid containing 4 conjugated double bonds, is toxic to human monocytic leukemia cells at concentrations of 5 microM or less."( Cytotoxic effect of cis-parinaric acid in cultured malignant cells.
Cornelius, AS; Kratz, DA; Spector, AA; Yerram, NR, 1991
)
2.03
"Methanol extracts of the hepatopancreas of mussels (Mytilus edulis) harvested at two locations (Ship Harbour and Wine Harbour) in eastern Nova Scotia, Canada, were found to be toxic to mice after intraperitoneal injection."( An incident of elevated levels of unsaturated free fatty acids in mussels from Nova Scotia and their toxic effect in mice after intraperitoneal injection.
Chadha, RK; Lawrence, JF; Ratnayake, WM; Truelove, JF, 1994
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
octadecatetraenoic acidA polyunsaturated fatty acid whose structure contains double bonds at any four positions of an 18-carbon straight chain.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (221)

TimeframeStudies, This Drug (%)All Drugs %
pre-199064 (28.96)18.7374
1990's98 (44.34)18.2507
2000's46 (20.81)29.6817
2010's11 (4.98)24.3611
2020's2 (0.90)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.55 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index24.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.24%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other218 (97.76%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]